Sonoma Pharmaceuticals Introduces New and Improved Acuicyn™ Antimicrobial Eyelid and Eyelash Hygiene Solution

PETALUMA, Calif., March 27, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today launched a new and improved Acuicyn™ Antimicrobial Eyelid and Eyelash Hygiene solution.  Formulated from a patent-protected 100% hypochlorous acid (HOCl) solution, the antimicrobial Acuicyn removes encrustation and debris, helping to manage red, itchy and inflamed eyes. 

Now available in customized shatter-proof containers, Acuicyn is a non-detergent-based proprietary solution of pure 100% antimicrobial hypochlorous acid.  It is now available via a doctor’s prescription.  Safe as saline, Acuicyn doesn’t sting or burn making for pain-free application. 

"I've recently switched over from using Avenova to Acuicyn because Sonoma is the original U.S. medical-grade hypochlorous acid company with a wide range of products that have helped patients across many therapeutic indications around the globe,” said Dr. Mary Boname OD, MS, FAAO, and president/owner at Montgomery Eye Care. “I could not be happier with the results.  Not only are my patients satisfied with cleaner and clearer eyes, Acuicyn’s cost is significantly less than the cost of Avenova.  I was pleased with Avenova, but I’m beyond thrilled with Acuicyn!"

Acuicyn is available by prescription from U.S. optometrists and ophthalmologists.  For more information visit
About Chronic Eyelid and Eyelash Conditions
Millions of people suffer from chronic eye conditions caused by microorganisms that take up residence on eyelids and eyelashes, resulting in myriad afflictions including dry eye, MGD, blepharitis, demodex and eye allergies. 

In particular, nearly 30 million Americans suffer from chronic blepharitis, a fairly common eye condition that causes irritation and inflammation of the eyelid margin where eyelashes join the eyelid.  While normally a mild condition, if not properly treated, blepharitis can worsen to the point of negatively impacting one’s vision.  An equal opportunity affliction, it impacts both children and adult, men and women, and people of all ethnicities.  One outcome of untreated blepharitis is the onset of meibomian gland dysfunction or what is commonly called MGD dry eye.  Often accompanied by discomfort and loss of optimum vision, MGD affects the quality of the tear film.     

A similar affliction is dry eye syndrome, which burdens over 100 million people worldwide.  As a result of natural aging and modern living, risk of this disease increases 35% for each decade after a person reaches the age of 40.  As people grow older, the production of oil in the body decreases, thus reducing tear production while increasing evaporation of tears, resulting in dryness of the eyes.  This is further exasperated by increased time in front of a computer screen. 

Finally, the eyelash mite, also known as demodex folliculitis, is a parasite found in the hair follicles of the face, particularly in the eyelash area.  When mites build up to a high level, it can cause infection as well as loss of eyelashes.  The situation can worsen by not washing the face before bed.  It is estimated that 50% of Americans are afflicted with the eyelash mites due to sleeping with their eye makeup on.    

About Sonoma Pharmaceuticals, Inc.
Sonoma is a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care. The company’s products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at

Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the “Company”). These forward-looking statements are identified by the use of words such as “believe,” “achieve,” and “strive,” among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company’s business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies,  as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission. The Company disclaims any obligation to update these forward-looking statements, except as required by law.

Sonoma®, Acuicyn™ and Microcyn® Technology are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.

Media and Investor Contact:

Sonoma Pharmaceuticals, Inc.
Dan McFadden
VP of Public and Investor Relations
(425) 753-2105

Primary Logo

Source: Sonoma Pharmaceuticals, Inc.